Ivan Kairatov is a distinguished biopharma expert whose career has been defined by a deep commitment to research, development, and technological innovation. With an intricate understanding of the drug development lifecycle, he has witnessed firsthand how targeted therapies can transform patient
The scientific community has long sought biological models that mirror the spontaneous and complex nature of human cancer without the need for artificial induction or genetic engineering in the laboratory environment. The lemon frost leopard gecko has emerged as a transformative subject in oncology
The clinical research community has long grappled with the invasive necessity of liver biopsies, yet the publication of the LITMUS Imaging Study in Nature Medicine marks a definitive turning point in the pursuit of non-invasive diagnostics. For decades, the liver biopsy stood as the undisputed gold
The pursuit of effective treatments for Duchenne muscular dystrophy has shifted focus toward managing cardiomyopathy, which currently stands as the most common cause of mortality for patients entering their second or third decade of life. Capricor Therapeutics recently faced significant headwinds
The financial architecture of modern drug development has undergone a radical transformation, positioning the Clinical Trial Per-Patient Cost as the definitive barometer for operational success in a landscape defined by hyper-personalized medicine. No longer viewed as a static accounting figure,
The intersection of computational intelligence and molecular biology has revealed a shocking source for the next generation of life-saving medicine: the same infectious proteins responsible for devastating neurological disorders like Creutzfeldt-Jakob disease. Researchers at the Perelman School of
